Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.380 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	28,597
Open	7.380
Bid (Size)	7.390 (100)
Ask (Size)	7.470 (1,000)
Prev. Close	7.380
Today's Range	7.380 - 7.380
52wk Range	1.830 - 12.43
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX

March 26, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Reversal Alert: VTIX, MARA, IBRX, BATL, NDRA, EEIQ Gain Momentum as Multi-Sector Catalysts Build

March 26, 2026

Via AB Newswire

Performance

YTD	+265.3%	+265.3%
1 Month	-36.1%	-36.1%
3 Month	+244.9%	+244.9%
6 Month	+200.0%	+200.0%
1 Year	+165.5%	+165.5%

More News

Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations

March 26, 2026

Via TheNewswire.com

Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations

March 26, 2026

Via NewMediaWire

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

March 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations

March 24, 2026

Via TheNewswire.com

Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations

March 24, 2026

Via NewMediaWire

Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX

March 24, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets ↗

March 24, 2026

Via The Motley Fool

Most active stocks in Tuesday's session ↗

March 24, 2026

Via Chartmill

Why ImmunityBio Stock Is Down More Than 20% Today ↗

March 24, 2026

Via The Motley Fool

There are notable gap-ups and gap-downs in today's session. ↗

March 24, 2026

Via Chartmill

ImmunityBio Crashes On FDA Warning Over Anktiva Claims ↗

March 24, 2026

Via Benzinga

Why ImmunityBio Stock Is Up More Than 11% Today ↗

March 23, 2026

Via The Motley Fool

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

March 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Stocks Under $10: IBRX, VTIX, NDRA, SMX – 2026 Watch Now!

March 19, 2026

Via AB Newswire

Why Did IBRX Stock Jump 7% In Pre-Market Today? ↗

March 17, 2026

Via Stocktwits

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

March 17, 2026

From ImmunityBio, Inc.

Via Business Wire

IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗

March 17, 2026

Via Stocktwits

IBRX Stock Rises 3% Pre-Market: ImmunityBio Reports Breakthrough In NK Cell Therapy Production ↗

March 13, 2026

Via Stocktwits

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

March 13, 2026

From ImmunityBio, Inc.

Via Business Wire

IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact ↗

March 12, 2026

Via Stocktwits

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗

March 12, 2026

Via MarketBeat

IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst ↗

March 11, 2026

Via Stocktwits

IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗

March 09, 2026

Via Stocktwits

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 7.380

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 03/26/26 04:00 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 2.89B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.